Brief: Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Clinical Trials In ENPP1 Deficiency, ABCC6 Deficiency In Q1 2023

Inozyme Pharma

08/12/2022 13:44

Dec 8 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA INC -  PLANS TO REPORT TOPLINE DATA FROM
BOTH
ONGOING PHASE 1/2 CLINICAL TRIALS IN ENPP1 DEFICIENCY AND ABCC6
DEFICIENCY IN THE Q1 OF 2023
    * INOZYME PHARMA INC -  PHASE 1 DOSE ESCALATION PORTION OF
ONGOING
PHASE 1/2 CLINICAL TRIALS OF INZ-701 HAS EACH BEEN FULLY
ENROLLED
    * INOZYME PHARMA INC -  PHASE 2 EXTENSION PORTION OF TRIAL
INZ-701
IS ALSO ONGOING

Further company coverage:  INZY.O 
 ((Reuters.Briefs@thomsonreuters.com;))